Interannual variations in the Earth's radiative budget and the general circulation

August, 1972.Includes bibliographical references

Cloudiness, the planetary radiation budget, and climate

Spring 1978.Includes bibliographic references (pages 110-115).This research was sponsored in part under NASA Grant NGR 06-002-102.Covers not scanned.Print version deaccessioned 2020.Satellite planetary radiation budget measurements from the Nimbus 3 satellite for four semi-monthly periods along with a 29 month composite of measurements from six satellites are applied in a quantitative study to evaluate the effect of cloudiness on the planetary radiation budget. Annual and seasonal results are expressed as zonal, hemispherical and global mean values. The results show that for the planet as a whole the effect of "present day" clouds in reducing the absorbed shortwave flux is larger than their effect in reducing the long wave emitted flux. The difference between the two effects is significantly larger over oceans than over land. Similarly, the sensitivity to changes in cloud amount is greater in the shortwave absorbed flux than in the longwave flux emitted to space. It was also shown that the presence of clouds act to reduce the amplitude of the annual variation of the global planetary net radiation budget. One may hypothesize from the results of this study and the works of others that a uniform increase in global cloud amount (in the absence of changes in cloud top height, cloud albedo, other atmospheric constituents, and vertical temperature lapse rates) will decrease the global mean surface temperature until radiative equilibrium is restored

PhenoScanner: a database of human genotype-phenotype associations.

UNLABELLED: PhenoScanner is a curated database of publicly available results from large-scale genetic association studies. This tool aims to facilitate 'phenome scans', the cross-referencing of genetic variants with many phenotypes, to help aid understanding of disease pathways and biology. The database currently contains over 350 million association results and over 10 million unique genetic variants, mostly single nucleotide polymorphisms. It is accompanied by a web-based tool that queries the database for associations with user-specified variants, providing results according to the same effect and non-effect alleles for each input variant. The tool provides the option of searching for trait associations with proxies of the input variants, calculated using the European samples from 1000 Genomes and Hapmap. AVAILABILITY AND IMPLEMENTATION: PhenoScanner is available at www.phenoscanner.medschl.cam.ac.uk CONTACT: [email protected] information: Supplementary data are available at Bioinformatics online.This work was supported by the UK Medical Research Council [G66840, G0800270], Pfizer [G73632], British Heart Foundation [SP/09/002], UK National Institute for Health Research Cambridge Biomedical Research Centre, European Research Council [268834], and European Commission Framework Programme 7 [HEALTH-F2-2012-279233].This is the author accepted manuscript. It is currently under an indefinite embargo pending publication by Oxford University Press

Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation A serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial

ObjectivesThe aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effects of polymer-based, paclitaxel-eluting stents on in-stent neointima formation and late incomplete stent apposition.BackgroundThe TAXUS-IV trial demonstrated that the slow-release, polymer-based, paclitaxel-eluting stent reduces angiographic restenosis and the need for repeat revascularization procedures. Serial IVUS studies reveal details of the pattern of vascular responses provoked by stent implantation that provide insight into device safety and efficacy.MethodsIn the TAXUS-IV trial, patients were randomized to the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scientific Corp., Natick, Massachusetts). As part of a formal substudy, complete volumetric IVUS data were available in 170 patients, including 88 TAXUS patients and 82 controls, at implantation and at nine-month follow-up.ResultsNo baseline differences were present in the clinical characteristics or IVUS parameters between the control and TAXUS groups. At nine-month follow-up, IVUS lumen volumes were larger in the TAXUS group (123 ± 43 mm3vs. 104 ± 44 mm3, p = 0.005), due to a reduction in neointimal volume (18 ± 18 mm3vs. 41 ± 23 mm3, p < 0.001). Millimeter-by-millimeter analysis within the stent demonstrated uniform suppression of neointimal growth along the entire stent length. Late lumen loss was similar at the proximal edge of the stent between the two groups, and reduced with the TAXUS stent at the distal edge (p = 0.004). Incomplete stent apposition at nine months was observed in only 3.0% of control and 4.0% of TAXUS stents (p = 0.12).ConclusionsPolymer-based, paclitaxel-eluting TAXUS stents are effective in inhibiting neointimal tissue proliferation, and do not result in late incomplete stent apposition

Super-conservative interpretation of muon g-2 results applied to supersymmetry

The recent developments in theory and experiment related to the anomalous magnetic moment of the muon are applied to supersymmetry. We follow a very cautious course, demanding that the supersymmetric contributions fit within five standard deviations of the difference between experiment and the standard model prediction. Arbitrarily small supersymmetric contributions are then allowed, so no upper bounds on superpartner masses result. Nevertheless, non-trivial exclusions are found. We characterize the substantial region of parameter space ruled out by this analysis that has not been probed by any previous experiment. We also discuss some implications of the results for forthcoming collider experiments.Comment: 10 pages, latex, 3 fig

Roles of the RAF/MEK/ERK Pathway in Cell Growth, Malignant Transformation and Drug Resistance

Growth factors and mitogens use the Ras/Raf/MEK/ERK signaling cascade to transmit signals from their receptors to regulate gene expression and prevent apoptosis. Some components of these pathways are mutated or aberrantly expressed in human cancer (e.g., Ras, B-Raf). Mutations also occur at genes encoding upstream receptors (e.g., EGFR and Flt-3) and chimeric chromosomal translocations (e.g., BCR-ABL) which transmit their signals through these cascades. Even in the absence of obvious genetic mutations, this pathway has been reported to be activated in over 50% of acute myelogenous leukemia and acute lymphocytic leukemia and is also frequently activated in other cancer types (e.g., breast and prostate cancers). Importantly, this increased expression is associated with a poor prognosis. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. For example, in some cells, PTEN mutation may contribute to suppression of the Raf/MEK/ERK cascade due to the ability of activated Akt to phosphorylate and inactivate different Rafs. Although both of these pathways are commonly thought to have anti-apoptotic and drug resistance effects on cells, they display different cell lineage specific effects. For example, Raf/MEK/ERK is usually associated with proliferation and drug resistance of hematopoietic cells, while activation of the Raf/MEK/ERK cascade is suppressed in some prostate cancer cell lines which have mutations at PTEN and express high levels of activated Akt. Furthermore the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways also interact with the p53 pathway. Some of these interactions can result in controlling the activity and subcellular localization of Bim, Bak, Bax, Puma and Noxa. Raf/MEK/ERK may promote cell cycle arrest in prostate cells and this may be regulated by p53 as restoration of wild-type p53 in p53 deficient prostate cancer cells results in their enhanced sensitivity to chemotherapeutic drugs and increased expression of Raf/MEK/ERK pathway. Thus in advanced prostate cancer, it may be advantageous to induce Raf/MEK/ERK expression to promote cell cycle arrest, while in hematopoietic cancers it may be beneficial to inhibit Raf/MEK/ERK induced proliferation and drug resistance. Thus the Raf/MEK/ERK pathway has different effects on growth, prevention of apoptosis, cell cycle arrest and induction of drug resistance in cells of various lineages which may be due to the presence of functional p53 and PTEN and the expression of lineage specific factors. Originally published Biochim Biophys Acta, Vol. 1773, No. 8, August 200

Muon anomalous magnetic dipole moment in supersymmetric theories

We study the muon anomalous magnetic dipole moment in supersymmetric theories. The impact of the recent Brookhaven E821 experimental measurement on both model-independent and model-dependent supersymmetric parameter spaces is discussed in detail. We find that values of tan\beta as low as 3 can be obtained while remaining within the E821 one-sigma bound. This requires a light smuon; however, we show that, somewhat surprisingly, no model-independent bound can be placed on the mass of the lightest chargino for any tan\beta greater than or equal to 3. We also show that the maximum contributions to the anomalous magnetic moment are insensitive to CP-violating phases. We provide analyses of the supersymmetric contribution to the muon anomalous magnetic moment in dilaton-dominated supergravity models and gauge-mediated supersymmetry-breaking models. Finally, we discuss how other phenomena, such as $B(b\to s\gamma)$, relic abundance of the lightest superpartner, and the Higgs mass may be correlated with the anomalous magnetic moment, but do not significantly impact the viability of a supersymmetric explanation, or the mass limits obtainable on smuons and charginos.Comment: 28 page

Importance of Indigenous Peoples' lands for the conservation of Intact Forest Landscapes

Intact Forest Landscapes (IFLs) are critical strongholds for the environmental services that they provide, not least for their role in climate protection. On the basis of information about the distributions of IFLs and Indigenous Peoples’ lands, we examined the importance of these areas for conserving the world's remaining intact forests. We determined that at least 36% of IFLs are within Indigenous Peoples’ lands, making these areas crucial to the mitigation action needed to avoid catastrophic climate change. We also provide evidence that IFL loss rates have been considerably lower on Indigenous Peoples’ lands than on other lands, although these forests are still vulnerable to clearing and other threats. World governments must recognize Indigenous Peoples’ rights, including land tenure rights, to ensure that Indigenous Peoples play active roles in decision‐making processes that affect IFLs on their lands. Such recognition is critical given the urgent need to reduce deforestation rates in the face of escalating climate change and global biodiversity loss.Intact Forest Landscapes (IFLs) are critical strongholds for the environmental services that they provide, not least for their role in climate protection. On the basis of information about the distributions of IFLs and Indigenous Peoples' lands, we examined the importance of these areas for conserving the world's remaining intact forests. We determined that at least 36% of IFLs are within Indigenous Peoples' lands, making these areas crucial to the mitigation action needed to avoid catastrophic climate change. We also provide evidence that IFL loss rates have been considerably lower on Indigenous Peoples' lands than on other lands, although these forests are still vulnerable to clearing and other threats. World governments must recognize Indigenous Peoples' rights, including land tenure rights, to ensure that Indigenous Peoples play active roles in decision-making processes that affect IFLs on their lands. Such recognition is critical given the urgent need to reduce deforestation rates in the face of escalating climate change and global biodiversity loss.Peer reviewe